Florence Agyemang-Bioh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florence Agyemang-Bioh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Gifty Boateng
National Public Health and Reference Laboratory, Ghana Health Service, Accra, Ghana
3 shared publications - Bright Ayensu
National Public Health and Reference Laboratory, Harley Street, Korle Bu Teaching Hospital, Accra P.O. Box GP300, Ghana
2 shared publications - Felix Sorvor
National TB Control Programme, Korle Bu Teaching Hospital, Accra P.O. Box KB493, Ghana
2 shared publications - Franklin Asiedu-Bekoe
Public Health Division, Ghana Health Service, Korle Bu Teaching Hospital, P.M.B. Ministries, Accra P.O. Box MB582, Ghana
2 shared publications - Lorreta Antwi
National Public Health and Reference Laboratory, Accra, Ghana
2 shared publications - Richard Kutame
National Public Health and Reference Laboratory, Harley Street, Korle Bu Teaching Hospital, Accra P.O. Box GP300, Ghana
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Public Health
- Vol. 2026 (1)
IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.
- 1 January 2026
- Published by Wiley in Advances in Public Health
- Vol. 2026 (1)
Open AccessIFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.
- Open Access
- 25 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (19) , 2130
Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis
Interferon-gamma release assays (IGRAs) have gained attention for the diagnosis of latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, the IGRA’s performance varies across different populations. This study evaluated the diagnostic performance of three IGRAs (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays as per the manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had sensitivity of 78.5–87.3% and specificity of 82.9–90.0%. These findings indicate that while the three IGRAs offer similar diagnostic accuracy, the variations in specificity and limited data on assays like TBF-FIA require further investigation.
- 25 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (19) , 2130
Open AccessEvaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis
Interferon-gamma release assays (IGRAs) have gained attention for the diagnosis of latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, the IGRA’s performance varies across different populations. This study evaluated the diagnostic performance of three IGRAs (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays as per the manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had sensitivity of 78.5–87.3% and specificity of 82.9–90.0%. These findings indicate that while the three IGRAs offer similar diagnostic accuracy, the variations in specificity and limited data on assays like TBF-FIA require further investigation.
- Open Access
- 22 August 2024
- Published by MDPI AG in Preprints.org
Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis
Interferon-gamma release assays (IGRAs) gained attention for diagnosing latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, IGRA performance varied across different populations. This study evaluated the diagnostic performance of three IGRA assays (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays per manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity, but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had a sensitivity of 78.5%-87.3% and a specificity of 82.9%-90.0%. These findings indicated that while the three IGRA assays offered similar diagnostic accuracy, variations in specificity and limited data on point-of-care assays like TBF-FIA required further investigation.
- 22 August 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis
Interferon-gamma release assays (IGRAs) gained attention for diagnosing latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, IGRA performance varied across different populations. This study evaluated the diagnostic performance of three IGRA assays (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays per manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity, but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had a sensitivity of 78.5%-87.3% and a specificity of 82.9%-90.0%. These findings indicated that while the three IGRA assays offered similar diagnostic accuracy, variations in specificity and limited data on point-of-care assays like TBF-FIA required further investigation.